Bringing together CFOs, sponsors, and partners across the biotech ecosystem to discuss capital markets readiness, valuation drivers, and artificial intelligence.
The operating model of our clients in the life sciences sector is evolving quickly.
Leading companies are increasingly using artificial intelligence and better data to drive smarter clinical and capital allocation decisions, generate value in their exit narrative, extend runway, and prepare to scale rapidly once commercial efficacy is proven. Watch the highlights from our second annual BioBoston summit, where over 120 executives gathered to discuss the path forward for the industry.
